Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.33 |
| ▸ | HRH1 | P35367 | 4/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11826759 | 0.88 | HDAC4 (0.42) | HDAC4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7963641 | 0.86 | PSEN1 (0.41) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL4431082 | 0.82 | PSEN1 (0.49) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL2294184 | 0.78 | ADRA1A (0.43) | HDAC4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11825289 | 0.77 | HDAC4 (0.48) | HDAC4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17543073 | 0.75 | PSEN1 (0.42) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL31459053 | 0.74 | HDAC4 (0.44) | HDAC4ADRA1AADRA1DADRA1B | |
| SCHEMBL1559063 | 0.74 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16897516 | 0.73 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1557008 | 0.73 | MEN1 (0.39) | HDAC4PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2009156100-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| EP-0034415-B1 | 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-05-30 | — | — | EP | disclosed |
| US-4369184-A | ANTIHISTAMINES; HETEROCYCLIC NITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-18 | — | — | US | disclosed |
| EP-0034415-A1 | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | ROCK1, MYLK, ROCK2 | HDAC4 1668/4885PDE4A 346/4885PDE4B 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.